Akebia TherapeuticsAKBA
About: Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
Employees: 181
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
230% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 23
93% more capital invested
Capital invested by funds: $203M [Q1] → $391M (+$188M) [Q2]
68% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 19
61% more call options, than puts
Call options by funds: $1.97M | Put options by funds: $1.23M
8% more funds holding
Funds holding: 144 [Q1] → 156 (+12) [Q2]
4.37% more ownership
Funds ownership: 36.56% [Q1] → 40.93% (+4.37%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Matthew Caufield | 159%upside $8 | Buy Assumed | 4 Jun 2025 |
Financial journalist opinion
Based on 10 articles about AKBA published over the past 30 days
